A Dose Escalation Study of Pegylated Liposomal Doxorubicin (Caelyx) in Combination with Capecitabine (Xeloda) in Patients with Refractory Solid Tumors

Publisher： Karger

E-ISSN： 1423-0232|69|6|463-469

ISSN： 0030-2414

Source： Oncology, Vol.69, Iss.6, 2006-02, pp. : 463-469

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dose Escalation Study on Oxaliplatin and Capecitabine (Xeloda) in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 66, Iss. 4, 2004-06 ,pp. : 253-259

Karger

Access to resources Recommend Favorite

A Dose-Escalation Study of Pegylated Liposomal Doxorubicin and Oxaliplatin in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 190-196

Karger

Access to resources Recommend Favorite

Phase I Study of Paclitaxel (Taxol) and Pegylated Liposomal Doxorubicin (Caelyx) Administered Every 2 Weeks in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 62, Iss. 3, 2002-06 ,pp. : 216-222

Karger

Access to resources Recommend Favorite

A Dose Escalation Study of the Biweekly Administration of Paclitaxel, Oxaliplatin and Capecitabine in Patients with Advanced Solid Tumors

By  

Oncology, Vol. 72, Iss. 1-2, 2007-11 ,pp. : 45-50

Karger

Access to resources Recommend Favorite

Pegylated Liposomal Doxorubicin (Caelyx®) in Metastatic Breast Cancer: A Community-Based Observation Study

By  

Oncology, Vol. 72, Iss. 3-4, 2007-12 ,pp. : 147-151

Karger

Access to resources Recommend Favorite